Business Context and Reporting Period
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on precision medicines for cancer. The filing covers the quarterly period ended June 30, 2025. The company's lead product candidate is ziftomenib, a menin inhibitor for acute myeloid leukemia (AML), which is currently under Priority Review by the FDA with a PDUFA target action date of November 30, 2025. The company also has two other product candidates in development: KO-2806 and tipifarnib.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenue | $15.3 million | $29.4 million | $0 |
| Net Loss | $(66.1) million | $(123.6) million | $(100.4) million |
| Net Loss Per Share | $(0.75) | $(1.41) | $(1.18) |
| Operating Expenses | $88.0 million | $166.8 million | $110.9 million |
| Cash & Short-Term Investments | $630.7 million (as of June 30, 2025) | ||
| Accumulated Deficit | $(1.02) billion (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $15.3 million in collaboration revenue for Q2 2025, compared to $0 in Q2 2024. This is driven by the Kyowa Kirin Collaboration and License Agreement, including revenue from development services and a $45.0 million milestone payment triggered by the FDA's acceptance of the ziftomenib NDA.
- Expense Growth: Research and development (R&D) expenses increased significantly to $62.8 million in Q2 2025 from $39.7 million in Q2 2024. This increase is primarily due to costs associated with the registration-directed clinical trial of ziftomenib and combination trials.
- Liquidity Position: Cash and cash equivalents decreased from $224.5 million at year-end 2024 to $81.9 million at June 30, 2025, while short-term investments increased to $548.8 million. Total cash, cash equivalents, and short-term investments stood at $630.7 million.
- Contract Liabilities: Contract liabilities increased to $301.9 million (comprising $49.4 million current and $252.5 million long-term) due to the upfront payment and allocated transaction price from the Kyowa Kirin agreement.
Outlook, Risks, and Management Commentary
- Regulatory Milestone: The FDA granted Priority Review for the ziftomenib NDA for relapsed/refractory NPM1-mutant AML. The company expects a decision by November 30, 2025.
- Clinical Progress: Positive data from the KOMET-001 and KOMET-007 trials were presented at ASCO and EHA. The company plans to initiate Phase 3 trials (KOMET-017) in the second half of 2025.
- Liquidity Runway: Management believes current cash and investments, combined with anticipated collaboration funding, are sufficient to fund operations into 2027 and support the ziftomenib AML program through commercialization in the frontline setting.
- Risks: Key risks include the uncertainty of FDA approval for ziftomenib, the potential for the Kyowa Kirin collaboration to be terminated or underperform, reliance on third-party manufacturers, and the need for substantial additional capital in the future.
Investor Verification Checklist
- FDA Decision Date: Verify the November 30, 2025 PDUFA date for the ziftomenib NDA and monitor for any Complete Response Letters.
- Collaboration Terms: Review the specific milestones and cost-sharing obligations under the Kyowa Kirin agreement to understand future revenue recognition and expense sharing.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the $630.7 million liquidity position to validate the 2027 runway estimate.
- Phase 3 Initiation: Confirm the start dates for the KOMET-017 Phase 3 trials in the second half of 2025.
- Debt Covenants: Review the minimum cash covenant requirements under the term loan facility, which vary based on FDA approval status and market capitalization.